Advanced Filters
noise

influenza Clinical Trials

A listing of influenza medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 115 clinical trials
A Amandine FRY

Effectiveness of a Nasal Spray on Viral Respiratory Infections

There is no cure for cold or flu, most people recover in about within two weeks. Paracetamol may be used to reduce aches or treat fever, headache, or body aches. Antiviral solutions ranging from simple universal saline solutions to novel compounds have been proposed to provide a temporary barrier to …

18 - 84 years of age Both Phase N/A
K Kyndra Woosley, MS

Magnesium Citrate Supplementation on Hand Grip Strength

The purpose of this research study is to determine the effectiveness of magnesium on handgrip strength using the more bioavailable magnesium citrate.

18 - 100 years of age Both Phase N/A
K Khadija Siddiqua

64Cu-GRIP B in Patients With Advanced Malignancies

This phase I/II clinical trial evaluates if using a radiotracer targeting granzyme B, 64-copper granzyme targeting restricted interaction peptide specific to family member B (64 Cu-GRIP B) with positron emission tomography (PET) imaging can be safe and useful for detecting granzyme B (GrB) in patients with advanced cancers that has …

18 - 100 years of age Both Phase 1/2
X Xavier Poiré, MD

Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-intensity Conditioning

The present project aims at comparing two conditioning regimens (FM-PTCy vs FM-ATG). The hypothesis is that one or the two regimens will lead to a 2-year cGRFS rate improvement from 30% (the cGRFS rate with FM without ATG/PTCy) to 45% (Pick-a-winner phase 2 randomized study).

18 - 75 years of age Both Phase 2
D Dag Kvale, MD/PhD

H7HLAII DNA Influenza Vaccine

The purpose of this study is to assess safety and immunogenicity of H7HLAII, a DNA vaccine encoding influenza hemagglutinin (HA) from influenza A/Shanghai/2/2013 (H7N9) directed to cells expressing human leukocyte antigen class II (HLAII) molecules, for prophylaxis of pandemic H7N9 influenza infection in healthy volunteers.

18 - 55 years of age Both Phase 1
B Barnaby Young, Dr

Immunogenicity Trial of 3 Influenza Vaccines

This study is a prospective randomised trial of 3 influenza vaccine formulations with different manufacturing processes: 1) egg-grown (QIV-E); 2) cell-grown (QIV-C); and 3) recombinant protein (QIV-R). The main objective is to compare the antibody responses following influenza vaccination among these 3 vaccines to determine whether recombinant vaccines offer superior …

21 - 49 years of age Both Phase 3
K Kurt Kristensen, MD, PhD

INfluenza VaccInation To Mitigate typE 1 Diabetes

In a multicenter, prospective, randomized, controlled clinical trial to compare influenza vaccination and placebo in sustaining β cell function in early type 1 diabetes mellitus.

7 - 17 years of age Both Phase 4
S Sokratis Apostolidis, MD

Study of Immune Responses to Influenza Vaccination

Better understanding of the immune responses to influenza vaccination is needed in order to understand situations of poor vaccine response. Adults will receive influenza vaccination and then have peripheral blood drawn at pre-defined intervals in order to study the lymphocyte responses.

18 - 100 years of age Both Phase 4
J Jiong HU

Flu-Bu-Mel Based Conditioning Regimen for Patients With Lymphoid Malignancies Undergoing Allo-HSCT

In this phase II clinical trial, we evaluate the efficacy and feasibility of conditioning regimen of fludarabine 150mg/m2, busulfan 9.6mg/kg, melphalan 100mg/m2 and etoposide 800mg/m2 in patients with lymphoid malignancies.

16 - 60 years of age Both Phase 2
A Abhinav Sharma

Timing of Influenza Vaccination in Patients With Heart Failure

Heart failure (HF) is one of the most common causes of hospital admission in Canada and costs the Canadian healthcare system over $1 billion annually. Influenza vaccination is an inexpensive strategy to prevent influenza infections and reduce an important trigger for HF decompensation and hospital readmission. Yet, the optimal timing …

18 - 100 years of age Both Phase N/A

Rewrite in simple language using AI